Physician profile
Humaira Khalid
NPI 1689642217
$5,233.64
in general payments reported to CMS, 2019-2025
45 companies · $874 in 2025
The $874 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $821 · 2020: $382 · 2021: $464 · 2022: $762 · 2023: $1,147 · 2024: $784 · 2025: $874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,805.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $808.45 | 2019-2025 | Rybelsus, Ozempic, Tresiba |
| Astrazeneca Pharmaceuticals LP | $529.90 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $389.75 | 2022-2025 | |
| Abbott Laboratories | $318.12 | 2019-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $316.51 | 2019-2025 | |
| Lilly USA, LLC | $316.50 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $193.37 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $187.16 | 2019-2025 | Otezla, Repatha, Repatha |
| Esperion Therapeutics, INC. | $179.29 | 2020-2022 | |
| Dexcom, INC. | $175.77 | 2021-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $173.24 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $167.32 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.25 | 2019-2023 | Synjardy, Tradjenta |
| Pfizer INC. | $128.28 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $126.20 | 2019-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Humaira Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.